COVID-19 and Hypertension: A Mini-Review of Their Mutual Effect

Udaya Ralapanawa1*

1Department of Medicine, University of Peradeniya, Sri Lanka.

Author’s contribution

The sole author designed, analysed, interpreted and prepared the manuscript.

Article Information

DOI: 10.9734/AJRID/2021/v8i230232

Editor(s):
(1) Dr. Win Myint Oo, Segi University, Malaysia.
(2) Dr. Hetal Pandya, Sumandeep Vidyapeeth, India.
(3) Dr. Jamal Hussaini, Universiti Teknologi MARA, Malaysia.

Reviewers:
(1) Ayan Chatterjee, Rishihood University, India.
(2) Yasser Fakri Mustafa, University of Mosul, Iraq.
(3) Hilman Zulkifli Amin, Universitas Indonesia, Indonesia.
(4) J. B. Kathiriya, Kamdhenu University, India.
(5) Audumbar Digambar Mali, Sahyadri College of Pharmacy, India.

Complete Peer review History: https://www.sdiarticle4.com/review-history/73055

Received 12 August 2021
Accepted 15 September 2021
Published 20 September 2021

ABSTRACT

Cases of Coronavirus disease are rapidly increasing across the world. Hypertension is the commonest co-morbidity among COVID-19 infected patients and hypertension is one of the determinants of severity of COVID-19. COVID-19 virus uses ACE-2 as an entry receptor and ACE-2 plays a vital role in blood pressure control in an individual. Certain antihypertensive medications may affect ACE-2 level and hence COVID-19 pathogenesis. At present, while the world’s focus is on the COVID-19, there is a danger that management of other illnesses like hypertension might be overlooked. It is highly recommended to take antihypertensive medications as directed and following healthy lifestyle practices like regular exercise, consuming low salt heart-healthy diet, maintaining a healthy weight and reducing stress, and practicing mindfulness even during this pandemic.

Keywords: Hypertension; COVID-19; health control; ACE-2.
1. INTRODUCTION

Cases of coronavirus disease-19 (COVID-19) are rapidly increasing across the world. According to the WHO, COVID-19 situation reported at 14 May 2021, more than 160 686 749 confirmed cases including 3,335,948 deaths have been reported via WHO. By 11 May 2021, around 1,264,164,553 vaccine doses have been administered globally [1]. The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus causing COVID-19, and the viruses that caused the past outbreaks of SARS and MERS are closely related. According to the published report cases, mortality rate of COVID-19 vary widely between countries. During the begging of 2021, a large number of cases were detected in Europe and United State and there was a significant decline of new cases towards March-April 2021 with the introduction of the COVID-19 vaccine. On the other hand, there is a significant surge of new cases in Asia including India towards April-May 2021[2,3]. According to the Bulletin released on 6th March 2020 by the American College of Cardiologists, the overall case-fatality rate for COVID-19 is 2.3% while the death rate shoots to 10.5% for people with cardiovascular diseases and 6.0% for people with hypertension [4]. Published data shows some specific comorbidities are associated with increased risk of infection and poor outcomes with increased severity of lung injury and mortality [5]. According to a retrospective cohort study done in China, the most common comorbidities reported were hypertension(30%), diabetes mellitus(19%), and coronary heart disease(8%) [6,7]. Another such study done in Wuhan, China, revealed that the most common comorbidities in individuals who developed acute respiratory distress syndrome were hypertension(27%), diabetes mellitus(19%), and cardiovascular disease(6%) [8,9]. As per Chinese National health Commission data, 35% of patients diagnosed with COVID-19 had hypertension [10,11]. A large study done in United State revealed an overall rate of hypertension was 56% among COVID-19 patients [12]. Accordingly, hypertension is a determinant of the severity of COVID-19 which needs further evaluation.

2. METHODOLOGY

Multiple search systems were utilized to recognise potentially relevant papers during the literature search. Searches were performed manually by the author and involved several sources, including high-impact journals, online databases (Medline, PubMed, ISI, IBSS, and Google Scholar), libraries (Elsevier ScienceDirect and Wiley). Reference lists of identified papers, relevant reviews, and meta-analyses were examined for additional articles. Studies published between 1990 to 2021 were included. The following Medical Subject Headings (MeSH) and keywords were used alone or in combination: hypertension, Coronavirus, Coronavirus infections, COVID-19, 2019-nCOV, ACE-2, andrenin-angiotensin-aldosterone system (RAAS). Initial study selection was performed via title and abstract screening by the author with the full-text screening of shortlisted publications were undertaken later. Publications in languages other than English and letters, editorials, conference abstracts, and comments were excluded. Then the selected articles were re-evaluated for relevance and duplication. The search strategy was conducted following previously published principles. Data abstraction was performed by the author after reading all selected articles. Detailed notes, impressions were written down and decided on which pieces of data possess values. Data were grouped into relevant categories and subcategories. Relationships among data sets were identified and analysed in detail and interpretations were made.

2.1 Main Text

Hypertension remains the leading cause of death worldwide, accounting for 10.4 million deaths annually [13]. In accordance with the Centre for Disease Control(CDC), almost 63% of adults over the age of 60 are hypertensive [14]. The estimated number of hypertensives shows a clear shift of numbers in high-income countries (HIC) (349 million) to low-middle income countries (LMIC) (1.04 billion) [13]. The large disparities in the regional burden of hypertension are accompanied by a low level of awareness, treatment, and control rates in LMIC when compare to HIC [13].

The regulation of blood pressure is complex and will be reviewed only briefly here. Neurogenic control, renin-angiotensin-aldosterone system (RAAS), arterial natriuretic peptides, eicosanoids, kallikrein-kinin systems, endothelial mechanisms, adrenal steroids, renomedullary vasodepression, and sodium and water metabolism are involved in the regulation of blood pressure [15].
2.2 RASS and Hypertension

The RASS plays a critical role in regulating multiple tissue and organ functions including cardiovascular, renal, lungs, and liver, and specifically involves in maintaining homeostasis of blood pressure, electrolyte balance, and inflammatory response [16,17,18]. Although RASS is considered as a systemic regulatory mechanism, over the past few decades findings have revealed that RASS plays a critical role by acting locally in various organs and tissue [16]. Deranged function of RASS leads to the pathogenesis of a number of diseases including hypertension, heart failure, myocardial infarction, diabetes, and inflammatory lung diseases [16].

In addition to the classical RASS pathway researchers have identified the counter-regulatory RASS pathway. The counter-regulatory RASS is made up of diverse peptides, receptors, and enzymes [19]. Angiotensin-converting enzyme 2 (ACE2) is a novel member of counter-regulatory RASS and it has emerged as a potent negative regulator of the classical RASS [13]. The imbalanced activity of the angiotensin-converting enzyme (ACE) and ACE2 locally or systemically leads to many disease pathogenesis including lung disease [13,20].

ACE2 is a type 1 transmembrane metallocarboxypeptidase with homology to ACE [21]. ACE2 neutralizes the inflammatory effects of angiotensin II, reduces the concentrations of proinflammatory cytokine interleukin-6, enhances the anti-inflammatory and antioxidant roles of angiotensin 1-7, increases the concentration of alveolar surfactant protein D, and triggers vasodilatation [22].

ACE-2 can negatively regulate classical RASS by degrading Angiotensin 11 to generate Angiotensin 1-7 and cleaving angiotensin 1 to generate angiotensin 1-9 [19]. ACE-2 has been shown to exhibit a protective function in the cardiovascular system and other organs [21]. Some preclinical studies have demonstrated that stimulating ACE2, can reduce blood pressure and lessen cardiovascular damage [19].

2.2.1 Role of ACE-2 in the pathogenesis of COVID 19

A number of recent research have shown that COVID-19 can infect various parts of the human body including the respiratory, cardiovascular, digestive, nervous, and urogenital system [9]. The life cycle of COVID-19 with the host consists of the following five steps: attachment, penetration, biosynthesis, maturation, and release [18]. COVID-19 utilizes ACE-2 as a cellular entry receptor [21,23]. Though ACE2 is widely distributed in the human body its high expression is confined to the endothelial cells of the arteries, arterioles, and venules of the heart and kidney [24]. Also ACE2 is present in many cell types and tissues including the lungs, heart, liver, and gastrointestinal tract [25,26]. In the lungs, ACE2 is highly abundant on type 2 pneumocytes [27]. As mentioned earlier, RASS is an important biochemical pathway in the body which is critical to regulate processes like blood pressure, inflammation, and wound healing. ACE2 is a vital component of the RASS pathway [27]. A protein called angiotensin II (ANG II) is a component of RASS. ANG II can increase blood pressure and augment inflammation. It also increases the damage to blood vessels linings and various types of tissue injury. ACE2 converts ANG II to other molecules that counteract the effects of ANG II [27]. When the COVID-19 virus binds to ACE2, a decrease in available ACE2 prevents ACE2 from performing its normal functions to regulate AGN II and more ANG II is available to injure tissues. This leads to injury, especially to the lungs and heart, in COVID-19 patients [27]. Though ACE2 is present in all people the quantity can vary among individuals and different tissues and cells. A study done in mice has found that lack of ACE2 is associated with severe injury in the heart, lungs, and other tissue types [27].

2.2.2 How does hypertension results in severe COVID-19 infection

According to the meta-analysis done by Pranata et al, hypertension is linked to poor outcomes in COVID-19 patients including mortality, severe COVID-19, adult respiratory distress syndrome, need for ICU care, and disease progression [22]. The association between hypertension and severe COVID-19 infection is complex [28,29]. Some believe that poorly controlled blood pressure can lead to chronic inflammation throughout the body which can damage blood vessels leading to dysregulation of the immune system. Oliveira et al stated that reducing the amount of the pro-inflammatory cytokines, which leads to a weaker immune function in hypertensives may contribute to this [30]. This leads to difficulty in fighting the virus, or a dangerous overreaction of the immune system to COVID-19 [28]. Another factor that exacerbates
the effect of the COVID 19 virus is endothelial dysfunction which commonly occurs in hypertensives [31].

It was believed that hypertensive patients have raised ACE 2 expression due to associated genetic polymorphism and the use of antihypertensive drugs like angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), which even though still controversial, may increase susceptibility and severity of COVID-19 [22]. But more recent data suggested that prescription and continuation of ACEIs/ARBs may in fact protect against SARS-CoV-2 infection and COVID-19 related deaths [29,32,33]. According to de Abajo, RASS inhibitors do not increase the severe COVID-19 risk and should not be discontinued to prevent a severe case of COVID-19 [34]. A meta-analysis done by Ssentongo revealed that prior use of RASS inhibitors was associated with lower risk mortality from COVID-19 in patients with hypertension. Further, they showed the protective effect of RASS inhibitors in hypertensive patients with COVID-19 [35]. Similarly meta-analysis done by Chan also concluded that treatment with RASS inhibitors was not associated with a higher possibility of a positive test for COVID-19 infection, disease severity, or mortality [36].

Cao et al found differences in the allele of the ACE2 gene and states such alleles differences may lead to a different response to COVID 19 among different populations [24,37]. Accordingly overexpression of ACE2 is considered as the main reason for hypertensive patients to get more severe COVID-19 illness [22].

According to Pranata et al, meta-regression analysis confirmed that the association between hypertension and increased composite poor outcome was influenced by gender (p=0.013), but not by age (p=0.233), diabetes (p=0.882) or cardiovascular diseases (p=0.464) [22]. More expression and activation of Angiotensin II type 1 receptors in hypertensive males may lead to vasoconstriction, pro-inflammatory response, increasing oxidative stress, leading to adult respiratory distress syndrome (ARDS) in severe COVID-19 compared to female [22,38]. Another postulation is oestrogen predispose towards good RAS in female causing less severe disease [22].

Possible thrombo-embolic complications and procoaguable state of COVID-19 are also mounting concern [39,40]. Various hypercoaguable states like inflammation, hypoxia, dehydration, immobilization, and diffuse intravascular coagulation have been described in COVID-19 [31]. Hypertension is also known to be associated with hypercoaguable state and it might lead to a worsening thrombotic milieu [31,41].

2.2.3 Management of hypertension during COVID-19 pandemic

At present, while the worlds focus is on the COVID-19, there is a danger that other illnesses might be overlooked. The public is urged not to attend emergency departments and clinics. It is also likely that patients are concerned about contracting the virus while attending the hospital and are staying away. As a result, there are reports of delayed presentation of acute medical emergencies and also the management of stable chronic illnesses like hypertension and diabetes are affected [31]. It is noted many hospitals worldwide have cancelled all in-patient care, including routine outpatients clinics, and moved towards telemedicine as part of social distancing measures [31]. But even in these circumstances, it is particularly important that blood pressure and blood sugar levels are monitored regularly as patients with diabetes and hypertension are at higher risk for complications of COVID-19 [31]. As mentioned previously hypertension is the most prevalent co-morbidity among patients admitted with COVID-19. Also hypertensive patients who develop COVID-19 are more likely to be admitted to hospitals than normotensives and carry poorer outcomes from COVID-19 [31].

One of the major problems during a pandemic is early conflicting data that can cause uncertainty and confusion in the management. At the start of this pandemic, concerns were raised regarding the safe use of ACEIs/ARBs. Discontinuation of these medications can precipitate uncontrolled blood pressure or heart failure which could contribute to morbidity and mortality in the infected patients [31]. Vaduganathan et al disagree with the discontinuation of ACEIs in stable COVID patients or people who susceptible to COVID-19. Cardiopulmonary protective effects of ACEI/ARBs are beneficial and both drugs group should be continued in COVID-19 patients [24,42]. Guo et al also concluded that ACEIs/ARBs should not discontinue for patients who have been on those medications for a long time in the context of COVID 19. They also stated that the use of ACEIs/ARBs might be a double-
edged sword in COVID-19 [7]. The use of ACEIs/ARBs can upregulate the expression and activity of ACE2 in the lungs, they play a dual role in COVID-19 [30]. On the one hand, a higher level of ACE2 might increase the susceptibility of cells to the virus. On the other hand, the activation of ACE2 might ameliorate the acute lung injury induced by the COVID-19 virus [7]. They further claimed that it would be unwise to discontinue these medications abruptly as the protective role of ACE2 in the respiratory system is supported by ample evidence, whereas the increased risk of infection is still a hypothesis [7]. A recent retrospective study from China which compares outcomes on hospitalized patients with COVID-19 with and without ACEI or ARBs for hypertension has suggested that in the former all-cause mortality was lower [31]. Considering these facts now guidance was issued advising that ACEIs/ARBs not to be discontinued in COVID-19 patients [43,44,45].

Even during the COVID-19 pandemic, it is paramount important to continue the guideline-based management of hypertension. Healthcare providers need to ensure that patients are appropriately advised and have access to their drugs. Patients should be made aware that despite the lockdown, hospitals and pharmacies are still open and Family physicians and General practitioners are still available for consultations, even if it is over the telephone [31].

2.2.4 How can people with hypertension reduce the risk of COVID-19

Meticulous blood pressure control and following appropriate safety measures like universal mask-wearing, regular use of hand sanitizer, and social distancing may help preventing severe COVID-19 [28]. It is highly recommended to take antihypertensive medications as directed and following healthy lifestyle practices like regular exercise, consuming a low salt heart-healthy diet, maintaining a healthy weight and reducing stress, and practicing mindfulness [28].

3. CONCLUSIONS

Currently, we all are in the process of learning about this novel virus, and information continues to mount. This pandemic has brought about a profound change in the social and economic lives of many. Further, it has changed the way health care is being delivered and prioritized. The current pandemic taught us how the management of chronic diseases and illnesses like hypertension should go back to the community and the patient.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES

1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]. [cited 2021 May 14]. Available: https://covid19.who.int/

2. Mortality Risk of COVID-19 - Statistics and Research - Our World in Data [Internet]. [cited 2021 May 14]. Available: https://ourworldindata.org/mortality-risk-covid

3. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-Dannenburg G, Thompson H, Walker PGT, Hu H, Dighe A, Griffin JT, Baguelin M, Bhatia S, Boonyasiri A, Cori A, Cucunubá Z, FitzJohn R, Gaythorpe K, Green W, Hamlet A, Hinsley W, Laydon D, Nedjati-Gilani G, Riley S, van Elsland S, Volz E, Wang H, Wang Y, Xi X, Donnelly CA, Ghani AC, Ferguson NM. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis [Internet]. 2020;20(6):669–77. [cited 2021 May 14]. Available: www.thelancet.com/infectionVol.

4. ACC Clinical Bulletin Focuses on Cardiac Implications of Coronavirus (COVID-19) - American College of Cardiology [Internet]. [cited 2021 May 14]. Available: https://www.acc.org/latest-in-cardiology/articles/2020/02/13/12/42/acc-clinical-bulletin-focuses-on-cardiac-implications-of-coronavirus-2019-ncov
5. Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19 [Internet]. Vol. 33, American Journal of Hypertension. Oxford University Press. 2020;373–4. [cited 2021 May 14]. Available: /pmc/articles/PMC7184512/

6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet [Internet]. 2020;395(10229):1054–62. [cited 2021 May 14]. Available: https://doi.org/10.1016/

7. Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc [Internet]. 2020;9(7):e016219. [cited 2021 May 16]. Available from: https://www.ahajournals.org/doi/10.1161/JAHA.120.016219

8. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med [Internet]. 2020;180(7):934–43. [cited 2021 May 14]. Available: https://jamanetwork.com/

9. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? [Internet]. The Lancet Respiratory Medicine. Lancet Publishing Group. 2020;8:e21. [cited 2021 May 15]. Available: /pmc/articles/PMC7118626/

10. Askin L, Tannverdi O, Askin HS. The effect of coronavirus disease 2019 on cardiovascular diseases [Internet]. Vol. 114, Arquivos Brasileiros de Cardiologia. Arquivos Brasileiros de Cardiologia. 2020;817–22. [cited 2021 May 22]. Available:https://doi.org/10.36660/abc.20200273

11. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system [Internet]. Vol. 17, Nature Reviews Cardiology. Nature Research. 2020;259–60. [cited 2021 May 22]. Available: https://doi.org/10.1001/jama.2020.1585

12. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area. JAMA - J Am Med Assoc [Internet]. 2020;323(20):2052–9. [cited 2021 Jun 7]. Available from: https://jamanetwork.com/

13. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension [Internet]. 2020;75(6):1334–57. [cited 2021 May 14]. Available from: http://ahajournals.org

14. COVID-19 and Hypertension: What We Know and Dont Know - American College of Cardiology [Internet]. [cited 2021 Jun 7]. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/07/06/08/15/covid-19-and-hypertension

15. Foëx P, Seif JW. Hypertension: Pathophysiology and treatment. Contin Educ Anaesthesia, Crit Care Pain [Internet]. 2004 Jun 1 [cited 2021 May 14];4(3):71–5. Available: https://academic.oup.com/bjaed/article/4/3/71/292146

16. Jia H. Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease [Internet]. Vol. 46, Shock. Lippincott Williams and Wilkins; 2016 [cited 2021 May 14]. 239–48. Available:https://journals.lww.com/shockjournal/Fulltext/2016/09000/Pulmonary_Angiotensin_Converting_Enzyme_2__ACE2__3.aspx
17. Pieruzzi F, Abassi ZA, Keiser HR. Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure. Circulation [Internet]. 1995 Nov 15 [cited 2021 May 14];92(10):3105–12. Available from: https://www.ahajournals.org/doi/abs/10.1161/01.cir.92.10.3105

18. Yuki K, Fujigoi M, Koutsogiannaki S. COVID-19 pathophysiology: A review [Internet]. Vol. 215, Clinical Immunology. Academic Press Inc.; 2020 [cited 2021 May 14], p. 108427. Available: /pmc/articles/PMC7169933/

19. Paz Ocarnanza M, Riquelme JA, García L, Jalil JE, Chiong M, Santos RAS, Lavandero S. Counter-regulatory renin–angiotensin system in cardiovascular disease [Internet]. Vol. 17, Nature Reviews Cardiology. Nature Research; 2020 [cited 2021 May 14], p. 116–29. Available from: www.nature.com/nrcardio

20. Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, Farzan M, Wohlford-Lenane C, Perlman S, McCray PB. ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia. J Virol [Internet]. 2005 Dec 15 [cited 2021 May 14];79(23):14614–21. Available from: https://pubmed.ncbi.nlm.nih.gov/16282461/

21. ACE-2 is shown to be the entry receptor for SARS-CoV-2: R&D Systems [Internet]. [cited 2021 May 14]. Available:https://www.rndsystems.com/resources/articles/ace-2-sars-receptor-identified

22. Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. JRAAS - J Renin-Angiotensin-Aldosterone Syst [Internet]. 2020 Apr 1 [cited 2021 May 15];21(2). Available:https://pubmed.ncbi.nlm.nih.gov/32408793/

23. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med [Internet]. 2005 Aug 10 [cited 2021 May 18];11(8):875–9. Available:http://www.nature.com/articles/nm1267

24. Bosso M, Thanaraj TA, Abu-Farha M, Alanbabei M, Abubaker J, Al-Mulla F. The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19. Vol. 18, Molecular Therapy - Methods and Clinical Development. Cell Press; 2020. p. 321–7. Available: /pmc/articles/PMC7167720/

25. Donohue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res [Internet]. 2000 Sep 1 [cited 2021 May 22];203(2):631–7. Available: /pmc/articles/PMC7167720/

26. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol [Internet], 2004 Jun [cited 2021 May 22];203(2):631–7. Available: http://www.circresaha.org.

27. What is the ACE2 receptor, how is it connected to coronavirus and why might it be key to treating COVID-19? The experts explain [Internet]. [cited 2021 May 16]. Available:https://theconversation.com/what-is-the-ace2-receptor-how-is-it-connected-to-coronavirus-and-why-might-it-be-key-to-treating-covid-19-the-experts-explain-136928

28. Hypertension, health inequities, and implications for COVID-19 - Harvard Health [Internet]. [cited 2021 May 15]. Available:https://www.health.harvard.edu/blog/hypertension-health-inequities-and-implications-for-covid-19-2020111821348

29. Sheppard JP, Nicholson BD, Lee J, McGagh D, Sherlock J, Koshiaris C, Oke J, Jones NR, Hinton W, Armitage L, Van Hecke O, Lay-Flurrie S, Bankhead CR, Liyanage H, Williams J, Ferreira F, Feher MD, Ashworth AJ, Joy MP, De Lusignan S, Hobbs FDR. Association between Blood Pressure Control and Coronavirus Disease 2019 Outcomes in 45 418 Symptomatic Patients with Hypertension: An Observational Cohort Study. Hypertension [Internet]. 2021 [cited 2021 May 18];77:846–55.
Melode Oliveira G, Inés M, Rossi D. Review Article Nephropathy and Renal Diseases Nephrol Renal Dis. 2020.

Nadar SK, Tayebjee MH, Stowasser M, Byrd JB. Managing hypertension during the COVID-19 pandemic [Internet], Vol. 34, Journal of Human Hypertension. Springer Nature; 2020 [cited 2021 May 16], p. 415–7.

Available from: /pmc/articles/PMC7224587/

Hippisley-Cox J, Young D, Coupland C, Channon KM, Tan PS, Harrison DA, Rowan K, Aveyard P, Pavord ID, Watkinson PJ. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: Cohort study including 8.3 million people. Heart [Internet]. 2020 Oct 1 [cited 2021 May 18];106(19):1503–11.

Available from: /pmc/articles/PMC7509391/

Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, Zhang X, Li Q, Li W, Yang S, Zhao X, Zhao Y, Wang H, Liu Y, Yin Z, Zhang R, Wang R, Yang M, Hui C, Wijns W, Mcevoy JW, Soliman O, Onuma Y, Serruys PW, Tao L, Li F. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J [Internet]. 2020 Jun 7 [cited 2021 May 18];41(22):2058–66.

Available from: /pmc/articles/PMC7314067/

de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, Laredo L, Laosa O, Centeno-Soto GA, Ángeles Gálvez M, Puerto M, González-Rojano E, Pedraza L, de Pablo I, Abad-Santos F, Rodríguez-Mañas L, Gil M, Tobías A, Rodríguez-Miguel A, Rodríguez-Puyol D, Barreire-Hernandez D, Zubiaur P, Santos-Molina E, Pinto-Sánchez E, Navares-Gómez M, Aparicio RM, García-Rosado V, Gutiérrez-Ortega C, Pérez C, Ascaso A, Elvira C. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet [Internet], 2020 May 30 [cited 2021 Jun 7];395(10238):1705–14.

Available from: www.bifap.org

Ssentongo AE, Ssentongo P, Heilbrunn ES, Lekoubou A, Du P, Liao D, Oh JS, Chinchilli VM. Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: Systematic review and meta-analysis. Open Hear [Internet]. 2020 Nov 7 [cited 2021 Jun 7];7(2):1353.

Available from: http://dx.doi.org/10.1136/chora.2020.018882

Cao Y, Li L, Feng Z, Wang S, Huang P, Sun X, Wen F, Huang X, Ning G, Wang W. Cell Discovery Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. [cited 2021 May 15]; Available from: http://creativecommons.org/licenses/by/4.0 /Correspondence:YananCao

Rabelo LA, Alenina N, Bader M. ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. Hypertens Res [Internet]. 2011 [cited 2021 May 16];34:154–60.

Available from: www.nature.com/hypertens

Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kapteijn FHJ, van Paassen J, Stals MAM, Huisman M V., Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res [Internet]. 2020 Jul 1 [cited 2021 May 18];191:145–7.

Available from: /pmc/articles/PMC7146714/

Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. J Clin Med [Internet]. 2020 May 11 [cited 2021 Jun 7];9(5):1417.

Available from: www.mdpi.com/journal/jcm

Nadar S, Lip GYH, Pini R. Hypertension and the prothrombotic state [1] (multiple letters). Vol. 41, Journal of the American

Available:https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.120.16472.

Ssentongo AE, Ssentongo P, Heilbrunn ES, Lekoubou A, Du P, Liao D, Oh JS, Chinchilli VM. Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: Systematic review and meta-analysis. Open Hear [Internet]. 2020 Nov 7 [cited 2021 Jun 7];7(2):1353.

Available from: http://dx.doi.org/10.1136/chora.2020.018882

Cao Y, Li L, Feng Z, Wang S, Huang P, Sun X, Wen F, Huang X, Ning G, Wang W. Cell Discovery Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. [cited 2021 May 15]; Available from: http://creativecommons.org/licenses/by/4.0 /Correspondence:YananCao

Rabelo LA, Alenina N, Bader M. ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. Hypertens Res [Internet]. 2011 [cited 2021 May 16];34:154–60.

Available from: www.nature.com/hypertens

Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kapteijn FHJ, van Paassen J, Stals MAM, Huisman M V., Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res [Internet]. 2020 Jul 1 [cited 2021 May 18];191:145–7.

Available from: /pmc/articles/PMC7146714/

Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. J Clin Med [Internet]. 2020 May 11 [cited 2021 Jun 7];9(5):1417.

Available from: www.mdpi.com/journal/jcm

Nadar S, Lip GYH, Pini R. Hypertension and the prothrombotic state [1] (multiple letters). Vol. 41, Journal of the American

Available:https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.120.16472.
College of Cardiology. Elsevier Inc.; 2003;1847.

42. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med [Internet]. 2020 Apr 23 [cited 2021 May 16];382(17):1653–9. Available: https://www.nejm.org/doi/full/10.1056/nejmsr2005760

43. Danser AHJ. Scientific Newsletter Update on Hypertension Management COVID-19 AND RAS BLOCKERS: A PHARMACOLOGY PERSPECTIVE [Internet]. [cited 2021 May 16]. Available:www.eshonline.org/spotlights/esh-statement-on-covid-19/

44. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 - American College of Cardiology [Internet]. [Cited 2021 May 16]. Available: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19

45. Kario K, Morisawa Y, Sukonthasarn A, Turana Y, Chia YC, Park S, Wang TD, Chen CH, Tay JC, Li Y, Wang JG. COVID-19 and hypertension—evidence and practical management: Guidance from the HOPE Asia Network [Internet]. Vol. 22, Journal of Clinical Hypertension. Blackwell Publishing Inc.; 2020 [cited 2021 Jun 7]. p. 1109–19. Available:https://onlinelibrary.wiley.com/doi/full/10.1111/jch.13917

© 2021 Ralapanawa; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle4.com/review-history/73055